Adimab enables its partners to rapidly expand their biologics pipelines through a broad array of technology access arrangements. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies and bispecifics that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. About AdimabĪdimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human lgGs. In addition, Adimab has transferred its platform for broad use to GSK, Biogen and Novo Nordisk. Adimab has also partnered with many mid-size and early-stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza, Arsanis and others. Adimab’s funded discovery partners include many leading pharmaceutical companies, such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Kyowa Hakko Kirin, Sanofi and others. Over the past 5+ years, Adimab has established funded discovery collaborations with over 30 companies.
#Kite pharma license#
Adimab will receive an undisclosed upfront payment, research fees and technical milestones, as well as license fees, certain additional milestones and royalties on any therapeutic CAR product sales that are optioned under the agreement. Kite will also have the option to exclusively license antibodies for development and commercialization as therapeutic CAR products. For each target, the agreement grants Kite the right to research antibodies generated during the collaboration for potential use in therapeutic CAR-T products. Kite and Adimab have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against selected targets. “Kite is focused on finding partnerships, such as this collaboration with Adimab, that help us establish a competitive advantage in the CAR-T space,” said Margo Roberts, Ph.D., Chief Scientific Officer of Kite. “Our platform can rapidly deliver a diverse panel of antibodies with varying affinities and ultra-high selectivity.” “Kite has established itself as a leader in the field of engineered autologous cell therapies, and we are excited to have the opportunity to work with them,” said Tillman Gerngross, Chief Executive Officer and co-founder of Adimab. The retroviral vector PG13-CD19-H3 is also used for development of other investigational therapies candidates such as KTE-X19 for acute lymphocytic leukaemia and mantle cell lymphoma.
Under the terms of the agreement, Adimab will use its proprietary platform to generate IgGs against multiple targets selected by Kite. Kite Pharma develops T-cell-based cancer immunotherapies for oncology by using CAR or a T-cell receptor (TCR), based on the type of cancer. Kite now has company in town chasing new cancer immunotherapy treatments.īillionaire physician Patrick Soon-Shiong’s NantWorks opened a state-of-the-art cancer treatment and diagnostics center on Mariposa Avenue last month that he said will one day mass produce natural killer cells.Adimab, LLC, the technology leader in the discovery of fully human antibodies and bispecifics, today announced a new collaboration with Kite Pharma, Inc., (Nasdaq:KITE). The seaside city is reinventing itself from a longtime aerospace center to a magnet for biotech firms and creative offices, touting more than $1 billion in new and planned development. “With Gilead’s expertise and support, we hope to fulfill that potential by rapidly accelerating our robust pipeline and next-generation research and manufacturing technologies for the benefit of patients around the world.”įounded in 2009, Kite is one of the biggest names to set up shop in El Segundo in recent years.
“CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers,” he said. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.”Īrie Belldegrun, chairman, president and CEO of Kite Pharma, said the company is “excited that Gilead, one of the most innovative companies in the industry, recognized this value and shares our passion for developing cutting-edge and potentially curative therapies for patients.” “We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. “The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients,” he said.
“The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers,” Gilead President and CEO John Milligan said in a statement.
0 kommentar(er)
